PPAR δ agonist GW501516 inhibits PDGF-stimulated pulmonary arterial smooth muscle cell function related to pathological vascular remodeling

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Liu, Guangjie ^a   Li, Xuan ^b,c   Li, Yan ^b,c   Tang, Xin ^b,c   Xu, Jie ^a   Li, Ran ^a   Hao, Peng ^b,c   Sun, Yongchang ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b NANKAI UNIVERSITY   (China)

^c TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

[2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; COLLAGEN; CYCLIN D1; CYCLIN D3; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1B; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; PLATELET DERIVED GROWTH FACTOR; CCL2 PROTEIN, HUMAN; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; THIAZOLE DERIVATIVE;

ARTICLE; CELL CYCLE; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE COURSE; GENE EXPRESSION; HUMAN; HUMAN CELL; LUNG BLOOD VESSEL; PULMONARY ARTERIAL SMOOTH MUSCLE CELL; PULMONARY ARTERY; PULMONARY HYPERTENSION; SMOOTH MUSCLE FIBER; UPREGULATION; WOUND HEALING; BIOSYNTHESIS; CELL DIFFERENTIATION; CELL MOTION; DRUG EFFECT; DRUG POTENTIATION; GENE EXPRESSION REGULATION; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TRANSCRIPTION INITIATION;

CELL DIFFERENTIATION; CELL MOVEMENT; CELL PROLIFERATION; CHEMOKINE CCL2; COLLAGEN; GENE EXPRESSION REGULATION; HUMANS; HYPERTENSION, PULMONARY; MOLECULAR TARGETED THERAPY; MYOCYTES, SMOOTH MUSCLE; NEOVASCULARIZATION, PATHOLOGIC; PLATELET-DERIVED GROWTH FACTOR; PPAR DELTA; PULMONARY ARTERY; THIAZOLES; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION;

EID: 84876531630     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/903947     Document Type: Article

References (40)

1. Rabinovitch M., Molecular pathogenesis of pulmonary arterial hypertension. Journal of Clinical Investigation 2008 118 7 2372 2379 2-s2.0-46749142123 10.1172/JCI33452 (Pubitemid 351949764)
2. Schermuly R. T., Ghofrani H. A., Wilkins M. R., Grimminger F., Mechanisms of disease: pulmonary arterial hypertension. Nature Reviews Cardiology 2011 8 8 443 455 2-s2.0-79960961583 10.1038/nrcardio.2011.87
3. Farkas L., Gauldie J., Voelkel N. F., Kolb M., Pulmonary hypertension and idiopathic pulmonary fibrosis: a tale of angiogenesis, apoptosis, and growth factors. The American Journal of Respiratory Cell and Molecular Biology 2011 45 1 1 15 10.1165/rcmb.2010-0365TR
4. Siegbahn A., Johnell M., Nordin A., Åberg M., Velling T., TF/FVIIa transactivate PDGFR β to regulate PDGF-BB-induced chemotaxis in different cell types: involvement of Src and PLC. Arteriosclerosis, Thrombosis, and Vascular Biology 2008 28 1 135 141 2-s2.0-37549043128 10.1161/ATVBAHA.107.155754
5. Perros F., Montani D., Dorfmüller P., Durand-Gasselin I., Tcherakian C., Le Pavec J., Mazmanian M., Fadel E., Mussot S., Mercier O., Hervé P., Emilie D., Eddahibi S., Simonneau G., Souza R., Humbert M., Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. The American Journal of Respiratory and Critical Care Medicine 2008 178 1 81 88 2-s2.0-46349109892 10.1164/rccm.200707-1037OC (Pubitemid 351919196)
6. Crosswhite P., Sun Z., Nitric oxide, oxidative stress and inflammation in pulmonary arterial hypertension. Journal of Hypertension 2010 28 2 201 212 2-s2.0-75149192272 10.1097/HJH.0b013e328332bcdb
7. Sertznig P., Seifert M., Tilgen W., Reichrath J., Present concepts and future outlook: function of peroxisome proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer. Journal of Cellular Physiology 2007 212 1 1 12 2-s2.0-34249948005 10.1002/jcp.20998 (Pubitemid 46876399)
8. Chawla A., Control of macrophage activation and function by PPARs. Circulation Research 2010 106 10 1559 1569 2-s2.0-77952997178 10.1161/CIRCRESAHA.110.216523
9. Lee J., Chung W. Y., The role played by the peroxisome proliferator-activated receptor- β / δ (PPAR β / δ) activator, GW501516, in control of fatty acid metabolism: a new potential therapeutic target for treating metabolic syndrome. Endocrinology 2011 152 5 1742 1744 2-s2.0-79955420151 10.1210/en.2011-0211
10. Chong H. C., Tan M. J., Philippe V., Tan S. H., Tan C. K., Ku C. W., Goh Y. Y., Wahli W., Michalik L., Tan N. S., Regulation of epithelial-mesenchymal IL-1 signaling by PPAR β / δ is essential for skin homeostasis and wound healing. Journal of Cell Biology 2009 184 6 817 831 2-s2.0-64049095625 10.1083/jcb.200809028
11. Ali F. Y., Egan K., FitzGerald G. A., Desvergne B., Wahli W., Bishop-Balley D., Warner T. D., Mitchell J. A., Role of prostacyclin versus peroxisome proliferator-activated receptor β receptors in prostacyclin sensing by lung fibroblasts. The American Journal of Respiratory Cell and Molecular Biology 2006 34 2 242 246 2-s2.0-32044471323 10.1165/rcmb.2005-0289OC (Pubitemid 43202472)
12. Li Y., Connolly M., Nagaraj C., Peroxisome proliferator-activated receptor-beta/delta, the acute signaling factor in prostacyclin-induced pulmonary vasodilation. The American Journal of Respiratory Cell and Molecular Biology 2012 46 3 372 379
13. Yang J., Li X., Al-Lamki R. S., Southwood M., Zhao J., Lever A. M., Grimminger F., Schermuly R. T., Morrell N. W., Smad-dependent and smad-independent induction of id1 by prostacyclin analogues inhibits proliferation of pulmonary artery smooth muscle cells in vitro and in vivo. Circulation Research 2010 107 2 252 262 2-s2.0-77955172689 10.1161/CIRCRESAHA. 109.209940
14. Tsai M. C., Chen L., Zhou J., Tang Z., Hsu T. F., Wang Y., Shih Y. T., Peng H. H., Wang N., Guan Y., Chien S., Chiu J. J., Shear stress induces synthetic-to-contractile phenotypic modulation in smooth muscle cells via peroxisome proliferator-activated receptor α / δ activations by prostacyclin released by sheared endothelial cells. Circulation Research 2009 105 5 471 480 2-s2.0-70149095915 10.1161/CIRCRESAHA.109.193656
15. Stacher E., Graham B. B., Hunt J. M., Gandjeva A., Jessup M., Grizzle W. E., Aldred M. A., Cool C. D., Tuder R. M., Modern age pathology of pulmonary arterial hypertension. The American Journal of Respiratory and Critical Care Medicine 2012 186 3 261 272 10.1164/rccm.201201-0164OC
16. Tuder R. M., Groves B., Badesch D. B., Voelkel N. F., Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. The American Journal of Pathology 1994 144 2 275 285 2-s2.0-0028282859 (Pubitemid 24165948)
17. Yue T. L., Nerurkar S. S., Bao W., Jucker B. M., Sarov-Blat L., Steplewski K., Ohlstein E. H., Willette R. N., In vivo activation of peroxisome proliferator-activated receptor- δ protects the heart from ischemia/reperfusion injury in Zucker fatty rats. Journal of Pharmacology and Experimental Therapeutics 2008 325 2 466 474 2-s2.0-42449113843 10.1124/jpet.107.135327 (Pubitemid 351574787)
18. Zhang J., Fu M., Zhu X., Xiao Y., Mou Y., Zheng H., Akinbami M. A., Wang Q., Chen Y. E., Peroxisome proliferator-activated receptor δ is up-regulated during vascular lesion formation and promotes post-confluent cell proliferation in vascular smooth muscle cells. Journal of Biological Chemistry 2002 277 13 11505 11512 2-s2.0-0037192764 10.1074/jbc.M110580200 (Pubitemid 34952920)
19. Zandbergen F., Mandard S., Escher P., Tan N. S., Patsouris D., Jatkoe T., Rojas-Caro S., Madore S., Wahli W., Tafuri S., Müller M., Kersten S., The G0/G1 switch gene 2 is a novel PPAR target gene. Biochemical Journal 2005 392 2 313 324 2-s2.0-29144451332 10.1042/BJ20050636 (Pubitemid 41796520)
20. Ikeda Y., Yonemitsu Y., Kataoka C., Kitamoto S., Yamaoka T., Nishida K. I., Takeshita A., Egashira K., Sueishi K., Anti-monocyte chemoattractant protein-1 gene therapy attenuates pulmonary hypertension in rats. The American Journal of Physiology 2002 283 5 H2021 H2028 2-s2.0-0036839051 (Pubitemid 35217037)
21. Girroir E. E., Hollingshead H. E., He P., Zhu B., Perdew G. H., Peters J. M., Quantitative expression patterns of peroxisome proliferator-activated receptor- β / δ (PPAR β / δ) protein in mice. Biochemical and Biophysical Research Communications 2008 371 3 456 461 2-s2.0-43549113326 10.1016/j.bbrc.2008.04.086
22. Coughlin S. R., Moskowitz M. A., Zetter B. R., Platelet-dependent stimulation of prostacyclin synthesis by platelet-derived growth factor. Nature 1980 288 5791 600 602 2-s2.0-0019192758 (Pubitemid 11223693)
23. Hamblin M., Chang L., Fan Y., Zhang J., Chen Y. E., PPaRs and the cardiovascular system. Antioxidants and Redox Signaling 2009 11 6 1415 1452 2-s2.0-65349091310 10.1089/ars.2008.2280
24. Coller H. A., What's taking so long? S-phase entry from quiescence versus proliferation. Nature Reviews Molecular Cell Biology 2007 8 8 667 670 2-s2.0-34547108336 10.1038/nrm2223 (Pubitemid 47106619)
25. Teunissen B. E. J., Smeets P. J. H., Willemsen P. H. M., de Windt L. J., van der Vusse G. J., van Bilsen M., Activation of PPAR δ inhibits cardiac fibroblast proliferation and the transdifferentiation into myofibroblasts. Cardiovascular Research 2007 75 3 519 529 2-s2.0-34447550270 10.1016/j.cardiores.2007.04.026 (Pubitemid 47080971)
26. Sue Y. M., Chung C. P., Lin H., Chou Y., Jen C. Y., Li H. F., Chang C. C., Juan S. H., PPAR δ -mediated p21/p27 induction via increased CREB-binding protein nuclear translocation in beraprost-induced antiproliferation of murine aortic smooth muscle cells. The American Journal of Physiology 2009 297 2 C321 C329 2-s2.0-68849103137 10.1152/ajpcell.00069.2009
27. Romanowska M., Al Yacoub N., Seidel H., Donandt S., Gerken H., Phillip S., Haritonova N., Artuc M., Schweiger S., Sterry W., Foerster J., PPAR δ enhances keratinocyte proliferation in psoriasis and induces heparin-binding EGF-like growth factor. Journal of Investigative Dermatology 2008 128 1 110 124 2-s2.0-37049018807 10.1038/sj.jid.5700943 (Pubitemid 350249370)
28. Piqueras L., Reynolds A. R., Hodivala-Dilke K. M., Alfranca A., Redondo J. M., Hatae T., Tanabe T., Warner T. D., Bishop-Bailey D., Activation of PPAR β / δ induces endothelial cell proliferation and angiogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology 2007 27 1 63 69 2-s2.0-33846577833 10.1161/01.ATV.0000250972.83623.61 (Pubitemid 46370477)
29. Wang D., Wang H., Guo Y., Ning W., Katkuri S., Wahli W., Desvergne B., Dey S. K., DuBois R. N., Crosstalk between peroxisome proliferator-activated receptor δ and VEGF stimulates cancer progression. Proceedings of the National Academy of Sciences of the United States of America 2006 103 50 19069 19074 2-s2.0-34047243022 10.1073/pnas.0607948103 (Pubitemid 350002829)
30. Schuster M., Zouboulis C. C., Ochsendorf F., Müller J., Thaaçi D., Bernd A., Kaufmann R., Kippenberger S., Peroxisome proliferator-activated receptor activators protect sebocytes from apoptosis: a new treatment modality for acne? British Journal of Dermatology 2011 164 1 182 186 2-s2.0-78650506416 10.1111/j.1365-2133.2010.10037.x
31. Michalik L., Desvergne B., Dreyer C., Gavillet M., Laurini R. N., Wahli W., PPAR expression and function during vertebrate development. International Journal of Developmental Biology 2002 46 1 105 114 2-s2.0-0036005782 (Pubitemid 34226309)
32. Muoio D. M., MacLean P. S., Lang D. B., Li S., Houmard J. A., Way J. M., Winegar D. A., Christopher Corton J., Lynis Dohm G., Kraus W. E., Fatty acid homeostasis and induction of lipid regulatory genes in skeletal muscles of peroxisome proliferator-activated receptor (PPAR) α knock-out mice. Evidence for compensatory regulation by PPAR δ Journal of Biological Chemistry 2002 277 29 26089 26097 2-s2.0-0037135623 10.1074/jbc.M203997200 (Pubitemid 34967092)
33. Gizard F., Amant C., Barbier O., Bellosta S., Robillard R., Percevault F., Sevestre H., Krimpenfort P., Corsini A., Rochette J., Glineur C., Fruchart J. C., Torpier G., Staels B., PPAR α inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a. Journal of Clinical Investigation 2005 115 11 3228 3238 2-s2.0-27644590901 10.1172/JCI22756 (Pubitemid 41567587)
34. Wakino S., Kintscher U., Kim S., Yin F., Hsueh W. A., Law R. E., Peroxisome proliferator-activated receptor γ ligands inhibit retinoblastoma phosphorylation and G1 → S transition in vascular smooth muscle cells. Journal of Biological Chemistry 2000 275 29 22435 22441 2-s2.0-0034698074 10.1074/jbc.M910452199 (Pubitemid 30621831)
35. Fu M., Zhu X., Wang Q., Zhang J., Song Q., Zheng H., Ogawa W., Du J., Chen Y. E., Platelet-derived growth factor promotes the expression of peroxisome proliferator-activated receptor γ in vascular smooth muscle cells by a phosphatidylinositol 3-kinase/Akt signaling pathway. Circulation Research 2001 89 11 1058 1064 2-s2.0-0035941410 (Pubitemid 34640874)
36. Sznaidman M. L., Haffner C. D., Maloney P. R., Fivush A., Chao E., Goreham D., Sierra M. L., LeGrumelec C., Xu H. E., Montana V. G., Lambert M. H., Willson T. M., Oliver W. R., Sternbach D. D., Novel selective small molecule agonists for peroxisome proliferator-activated receptor δ (PPAR δ): synthesis and biological activity. Bioorganic and Medicinal Chemistry Letters 2003 13 9 1517 1521 2-s2.0-12444289447 10.1016/S0960-894X(03)00207-5 (Pubitemid 36428550)
37. Zhang H., Pi R., Li R., Wang P., Tang F., Zhou S., Gao J., Jiang J., Chen S., Liu P., PPAR β / δ activation inhibits angiotensin II-induced collagen type I expression in rat cardiac fibroblasts. Archives of Biochemistry and Biophysics 2007 460 1 25 32 10.1016/j.abb.2007.01.028 (Pubitemid 46482426)
38. Borland M. G., Foreman J. E., Girroir E. E., Zolfaghari R., Sharma A. K., Amin S., Gonzalez F. J., Ross A. C., Peters J. M., Ligand activation of peroxisome proliferator-activated receptor- β / δ inhibits cell proliferation in human HaCaT keratinocytes. Molecular Pharmacology 2008 74 5 1429 1442 2-s2.0-54349120502 10.1124/mol.108.050609
39. Liang Y. J., Liu Y. C., Chen C. Y., Comparison of PPARdelta and PPARgamma in inhibiting the pro-inflammatory effects of C-reactive protein in endothelial cells. International Journal of Cardiology 2010 143 3 361 367
40. Yang X., Kume S., Tanaka Y., GW501516, a PPARdelta agonist, ameliorates tubulointerstitial inflammation in proteinuric kidney disease via inhibition of TAK1-NFkappaB pathway in mice. PloS One 2011 6 9 e25271